Q3 2025 EPS Estimates for Moderna, Inc. (NASDAQ:MRNA) Raised by William Blair

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at William Blair upped their Q3 2025 earnings estimates for shares of Moderna in a research report issued to clients and investors on Thursday, May 2nd. William Blair analyst M. Minter now forecasts that the company will post earnings per share of $1.30 for the quarter, up from their prior forecast of $1.25. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. William Blair also issued estimates for Moderna’s Q4 2025 earnings at $1.36 EPS, FY2026 earnings at ($0.72) EPS and FY2027 earnings at $3.16 EPS.

Several other brokerages have also recently weighed in on MRNA. HSBC reissued a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, May 2nd. Royal Bank of Canada boosted their price target on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. UBS Group increased their price objective on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group reissued a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $126.89.

Moderna Stock Down 0.9 %

Shares of NASDAQ:MRNA opened at $121.07 on Monday. The firm has a market cap of $46.40 billion, a P/E ratio of -7.73 and a beta of 1.57. Moderna has a 12-month low of $62.55 and a 12-month high of $142.79. The business has a fifty day simple moving average of $106.10 and a 200 day simple moving average of $95.05. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the firm earned $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% on a year-over-year basis.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently modified their holdings of MRNA. Ogorek Anthony Joseph NY ADV bought a new position in Moderna during the 4th quarter valued at $27,000. Arlington Trust Co LLC boosted its holdings in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the last quarter. Westside Investment Management Inc. bought a new stake in Moderna in the 1st quarter worth about $32,000. Rise Advisors LLC increased its stake in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after buying an additional 201 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the sale, the director now directly owns 2,026,931 shares of the company’s stock, valued at $224,827,186.52. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock valued at $14,822,576 in the last three months. Corporate insiders own 15.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.